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ABSTRACT
Biologically active natural products often contain interesting and complex structural
features and functionalities that make them attractive targets for synthetic chemists.  As
such, these natural products can serve as inspiration for the development of new reaction
methodology.
Cortistatin A contains a unique rearranged steroidal core and possesses potent anti-
angiogenic activity.  These features have made cortistatin A the target of many synthetic
efforts, including ours.  The progress toward the synthesis of the cortistatin A carbocyclic
core via an enyne-ene metathesis is discussed.  Our studies towards the construction of
the cortistatin A carbocyclic core yielded an interesting result, wherein an attempted SN2
inversion of a secondary mesylate afforded product with retention of stereochemistry.
Oxindole derived motifs are also prevalent in biologically active molecules.  More
specifically, 3,3-disubstituted oxindoles can be used to access pyrrolidinylspirooxindole
and pyrrolidinoindoline cores.  Herein, the development of a catalytic enantioselective
malonate alkylation of 3-halooxindoles to access enantiopure 3,3-disubstituted oxindoles
is detailed.  We then demonstrate that the enantiopure 3,3-disubstituted oxindoles derived
from this novel transformation can be used towards the construction of
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